Prevalence of transthyretin cardiac amyloidosis in patients with high-degree AV block.

Bradycardia Cardiomyopathy, Restrictive Epidemiology Pacemaker, Artificial

Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
27 Mar 2024
Historique:
received: 07 01 2024
accepted: 12 03 2024
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 27 3 2024
Statut: epublish

Résumé

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiac disorder caused by deposition of wild type or mutated transthyretin. As ATTR-CM is associated with conduction disease, we sought to determine its prevalence in patients with idiopathic high-degree atrioventricular (AV) block requiring permanent pacemaker (PPM) implantation. Consecutive patients aged 70-85 years undergoing PPM implantation for idiopathic high-degree AV block between November 2019 and November 2021 were offered a 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scan. Demographics, comorbidities, electrocardiographic and imaging data from the time of device implantation were retrospectively collected. 39 patients (79.5% male, mean (SD) age at device implantation 76.2 (2.9) years) had a DPD scan. 3/39 (7.7%, all male) had a result consistent with ATTR-CM (Perugini grade 2 or 3). Mean (SD) maximum wall thickness of those with a positive DPD scan was 19.0 mm (3.6 mm) vs 11.4 mm (2.7 mm) in those with a negative scan (p=0.06). All patients diagnosed with ATTR-CM had spinal canal stenosis and two had carpal tunnel syndrome. ATTR-CM should be considered in older patients requiring permanent pacing for high-degree AV block, particularly in the presence of left ventricular hypertrophy, carpal tunnel syndrome or spinal canal stenosis.

Identifiants

pubmed: 38538064
pii: openhrt-2024-002606
doi: 10.1136/openhrt-2024-002606
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: PME: consultancies and speaker fees Pfizer.

Auteurs

Douglas Cannie (D)

University College London, London, UK d.cannie@ucl.ac.uk.
St Bartholomew's Hospital, London, UK.

Kush Patel (K)

University College London, London, UK.
St Bartholomew's Hospital, London, UK.

Alexandros Protonotarios (A)

University College London, London, UK.
St Bartholomew's Hospital, London, UK.

Imogen Heenan (I)

University College London, London, UK.

Athanasios Bakalakos (A)

University College London, London, UK.
St Bartholomew's Hospital, London, UK.

Petros Syrris (P)

University College London, London, UK.

Leon Menezes (L)

University College London, London, UK.
St Bartholomew's Hospital, London, UK.

Perry M Elliott (PM)

University College London, London, UK.
St Bartholomew's Hospital, London, UK.

Classifications MeSH